Cholesterol in Menopause: Why LDL Rises and What to Do About It

Yes, cholesterol tends to rise during the menopause transition, especially LDL. In the Study of Women's Health Across the Nation (SWAN), LDL cholesterol increased by an average of roughly 10 mg/dL in the year before to the year after the final menstrual period, and total cholesterol and ApoB rose as well (Matthews et al., JACC 2009). The increase was linked to the transition itself, not just to getting older.

LDL cholesterol (low-density lipoprotein) is the type that can build up in artery walls. HDL is the type that helps clear it. You might expect HDL to help, but SWAN researchers later found that HDL's protective function may worsen around menopause, even when the number looks normal.

These changes are gradual, and many women feel nothing. Cholesterol does not cause symptoms, which is why blood tests matter. If your numbers were fine at 40 and are borderline at 52, menopause is a likely part of the story. For more on the bigger picture, see our article on [peripheral artery disease in menopause](/blog/peripheral-artery-disease-in-menopause-the-overlooked-risk).

Menopause raises LDL mainly because estrogen helps the liver pull LDL out of the blood, and when estrogen falls, that clearance slows. Estrogen increases the number of LDL receptors on liver cells, the docking sites that remove LDL particles from circulation. With fewer receptors, more LDL stays in the bloodstream.

Other shifts happen at the same time. Body fat tends to move toward the abdomen (visceral fat), which is linked to higher triglycerides and lower HDL. Insulin resistance may increase, and muscle mass often declines. Sleep loss and stress from hot flashes and night sweats can also affect metabolism.

Lipoprotein(a), or Lp(a), is a genetically determined, cholesterol-carrying particle that adds heart risk. Studies suggest Lp(a) may rise modestly after menopause. Because your Lp(a) level is mostly set by your genes, a single test is usually enough to know if you are affected.

In short, this is a biological change, not a failure of willpower. That is good news, because it means the fix is medical and practical, not moral.

It matters because heart disease is the leading cause of death in women, and risk rises after menopause. The American Heart Association's 2020 scientific statement on menopause and cardiovascular disease describes a worsening of cholesterol, blood pressure, fat distribution, and blood vessel function across the transition (El Khoudary et al., Circulation 2020).

Plaque builds over decades, so the numbers you carry in your 50s influence heart attack and stroke risk in your 60s and 70s. Reaching the transition with an already-high LDL or a family history of early heart disease raises the stakes.

There are also reproductive clues to risk. Early menopause (before 45), premature ovarian insufficiency, pregnancy complications like preeclampsia or gestational diabetes, and autoimmune diseases are recognized risk enhancers, meaning they nudge your risk higher than a basic calculator shows. It is worth telling your clinician about them.

The silver lining: cholesterol is one of the most modifiable risks. Women who address it in midlife can meaningfully lower their long-term risk. Our article on the [FRAX score](/blog/frax-score-in-menopause-calculating-your-fracture-risk) covers a similar risk-calculator approach for your bones.

Start with a standard lipid panel and ask your clinician whether an ApoB and a one-time Lp(a) test make sense for you. A basic panel reports total cholesterol, LDL, HDL, and triglycerides. Guidelines generally suggest checking every four to six years in low-risk adults, and more often if you have risk factors or are starting or changing treatment.

ApoB counts the number of atherogenic (plaque-forming) particles and can be more informative than LDL alone, especially if triglycerides are high or you have metabolic syndrome. Lp(a) is now recommended once in a lifetime for adults by several cardiology societies, because a high level (commonly above 50 mg/dL or 125 nmol/L) raises risk and is not fixed by diet.

For some women, a coronary artery calcium (CAC) scan can help decide about a statin when the choice is unclear. A score of zero is reassuring, and a high score points toward treatment.

Fasting is usually not required for a lipid panel. Bring your family history, especially any heart attack in a parent or sibling before age 55 (men) or 65 (women), because this changes the plan. And if you also track other menopause markers, our [symptom checklist](/blog/the-34-symptoms-of-perimenopause-a-complete-checklist) can help you and your clinician see the full picture.

You can lower cholesterol through food, movement, and weight management, and combined changes often reduce LDL by 10% to 20%. Results vary, and some women with genetic high cholesterol will still need medication.

• •Eat more soluble fiber. Oats, barley, beans, lentils, apples, and psyllium bind cholesterol in the gut. Aim for at least 25 grams of total fiber a day.
• •Swap saturated fat for unsaturated fat. Choose olive oil, nuts, avocado, and fish over butter, fatty red meat, and full-fat processed foods.
• •Add plant sterols and soy foods if you like them. Foods fortified with sterols can lower LDL modestly, and see our take on [soy and phytoestrogens](/blog/soy-phytoestrogens-in-menopause-what-research-shows).
• •Move daily. Aim for at least 150 minutes of moderate activity weekly. See [walking in menopause](/blog/walking-in-menopause-how-much-you-need-for-heart-and-bone-health).
• •Lift weights. Strength training improves body composition and insulin sensitivity.
• •Limit alcohol and stop smoking.
• •Prioritize sleep. Poor sleep is linked with worse cardiometabolic health.

Remember that diet alone typically reduces LDL less than a statin does. If your clinician recommends medication, that is not a failure of your lifestyle, it is an add-on to it.

Statins are the proven treatment for lowering LDL and heart attack risk, while hormone therapy can improve cholesterol numbers but is not recommended to prevent heart disease. This is a common point of confusion.

Statins lower LDL by roughly 30% to 50%, depending on the dose, and reduce heart attacks and strokes in people at elevated risk. Guidelines from the ACC/AHA (2018) recommend a risk conversation for adults 40 to 75, and treatment for higher-risk women. Side effects such as muscle aches are less common than feared in blinded trials. Other options like ezetimibe and PCSK9 inhibitors exist for those who need more or cannot take statins.

Hormone therapy lowers LDL and raises HDL somewhat, but large trials, including the Women's Health Initiative, did not show heart protection when started later in life. Menopause hormone therapy is prescribed to treat symptoms like hot flashes and to protect bones, not as a cholesterol drug. Timing matters, as we explain in [the HRT window of opportunity](/blog/the-hrt-window-of-opportunity-why-timing-matters). Oral estrogen can also raise triglycerides in some women, whereas transdermal forms have a smaller effect.

GLP-1 medications tend to modestly improve cholesterol and triglycerides as a side benefit of weight loss, and semaglutide reduced major cardiovascular events by 20% in the SELECT trial. In SELECT, adults with overweight or obesity and established heart disease but no diabetes had a hazard ratio of 0.80 for heart attack, stroke, or cardiovascular death (Lincoff et al., NEJM 2023).

In weight-loss trials, triglycerides typically drop by 10% to 20% or more, and LDL falls slightly. These medications are not substitutes for statins, though, and some people need both. If you take a statin, do not stop it just because you started a GLP-1 unless your clinician says so.

During rapid weight loss, cholesterol can shift temporarily, so it is reasonable to recheck a lipid panel three to six months after starting. If you are eating less and losing muscle, it is also worth watching protein; see [protein on GLP-1](/blog/protein-on-glp1-how-much-you-need-to-protect-muscle). Fat changes are part of the story too. Our article on [muscle loss with GLP-1s and menopause](/blog/muscle-loss-glp1-menopause-double-risk) covers the body composition side.